Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ABRAXANE

« Back to Dashboard
Abraxane is a drug marketed by Abraxis Bioscience and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug.

The generic ingredient in ABRAXANE is paclitaxel. There are sixty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paclitaxel profile page.

Summary for Tradename: ABRAXANE

Suppliers: see list1

Pharmacology for Tradename: ABRAXANE

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition

Clinical Trials for: ABRAXANE

Hepatic Arterial Infusion (HAI) of Abraxane
Status: Active, not recruiting Condition: Liver Cancer; Advanced Cancers; Solid Tumors

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Status: Recruiting Condition: Bladder Cancer

HAI Abraxane With Gemcitabine and Bevacizumab
Status: Completed Condition: Advanced Cancers

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Status: Recruiting Condition: Relapsed or Refractory Multiple Myeloma

Safety and Efficacy Study of Abraxane Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
Status: Active, not recruiting Condition: Pancreatic Neoplasms

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Status: Terminated Condition: Breast Neoplasms; Neoplasm Metastasis

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Status: Recruiting Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Status: Recruiting Condition: Melanoma

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Status: Recruiting Condition: Colorectal Cancer; Cancer of Gastrointestinal Tract

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Status: Completed Condition: Breast Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Bioscience
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes8,853,260<disabled>Y<disabled>
Abraxis Bioscience
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes8,268,348<disabled><disabled>
Abraxis Bioscience
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes7,820,788<disabled>Y<disabled>
Abraxis Bioscience
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes8,138,229<disabled>Y<disabled>
Abraxis Bioscience
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn